GILD Stock Analysis: Gilead Sciences Is Still Undervalued (GILD)

Gild Stock Analysis: Summary

  • Gilead Sciences’ stock price has increase over 19% so far this year due to its extremely successful hepatitis C drug solutions.gild stock analysis
  • There is some concern about sales growth for these drugs going forward, but they are overblown.
  • There is upside potential for the stock in the hepatitis B market, made evident by recent events.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that develops and creates innovative medicines to meet unmet medical needs. Its main areas of focus are liver diseases such as hepatitis C virus (HCV) infection and hepatitis B virus (HBV) infection, as well as human immunodeficiency virus (HIV) and cardiovascular and respiratory conditions.

The stock price has climbed 19.31% so far this year. The company has been able to grow revenue rapidly, with sales growth of 51.9% on a year-over-year basis during the most recent earnings report on April 30th.

The continued success of the HCV drugs Sovaldi and Harvoni and the possibility of a deal to enter into the HBV market make the stock bullish during the rest of the year. At this price level, I Know First algorithm is bullish on Gilead Sciences.

Read The Full Seeking Alpha Article